Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05375942 · ClinicalTrials.gov registry record
This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 255
- Enrollment target
NCT05375942: Completed study, sponsored by Pfizer.
NCT05375942 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 255 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05375942 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 255 participants
- Enrollment target
Study Summary
This is a retrospective observational study looking at the characteristics and outcomes of participants taking Inflectra using the CorEvitas Rheumatoid Arthritis Registry.
Primary Outcome
Clinical disease activity index (CDAI) was the numerical sum of 4 outcome parameters: tender and swollen joint count based on a 28-joint assessment, participant global assessment and physician global assessment assessed on 0 to 10 millimeter (mm) visual analogue scale (VAS) where 0 mm = minimum possible pain (best) and 100 mm = maximum possible pain (worst). Total score for CDAI ranged from 0 to 76 with higher score indicating greater disease activity. Participants who achieved LDA had CDAI scor
Interventions
- DRUG Inflectra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2022-11-11 |
| Est. Completion | 2022-11-11 |
What the finished NCT05375942 record still lists
NCT05375942 is an observational study that tracks outcomes without assigning an intervention. The registered 255 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Inflectra is the first listed.
NCT05375942 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05375942 about?
NCT05375942 is a clinical study titled "This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry". This is a retrospective observational study looking at the characteristics and outcomes of participants taking Inflectra using the CorEvitas Rheumatoid Arthritis Registry.
What is the current status of trial NCT05375942?
This trial is currently completed. The enrollment target is 255 participants. The study started on 2022-11-11. Estimated completion is 2022-11-11.
What interventions are being tested in trial NCT05375942?
The interventions under investigation include: Inflectra (DRUG).
Who is sponsoring clinical trial NCT05375942?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04623424 · 255 participants
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
- NCT05114798 · 255 participants · NA
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
- NCT05336188 · 255 participants · Phase 2
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
- NCT05486637 · 255 participants · Early Phase 1
Vocal Emotion Communication With Cochlear Implants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI